Overall survival (OS) & (MFS) in men ... - Advanced Prostate...

Advanced Prostate Cancer

22,350 members28,110 posts

Overall survival (OS) & (MFS) in men with biochemical relapse (BCR) after radical prostatectomy / defer ADT treatment til metastatic

George71 profile image
7 Replies

"ADT prior to mets may not improve QoL or OS in BCR prostate cancer and may result in irreversible adverse events at high costs. Early use of novel androgen receptor targeting drugs (NARTD) prolonged MFS in nonmetastatic-castration resistant prostate cancer (nmCRPC). However, clinical details prior to castration resistance and explicit criteria for starting ADT were not given. We hypothesize that deferring ADT until mets results in outcomes comparable to those reported with early ADT, irrespective of NARTD used in nmCRPC."

Methods:

Retrospective review of men who underwent RP from1983 - 2014 within Johns Hopkins and the Center for Prostate Disease Research Multi-Center National Database, developed BCR and did not receive ADT until metastasis. Kaplan-Meier estimates of MFS and OS were defined from RP to event/last follow-up. Multivariable Cox proportional hazard models identified predictive factors.

Results

Table852P

PSADT

Overall < =6 months < =10 months

# developed M + 595 (20%) 198 (45%) 309 (38%)

Median MFS (all) not reached 12 (8-16) years 16 (15-21) years

Median MFS (M+ only) 6 (6-7) years 3 (3-4) years 4 (4-5) years

Median OS 21 (20-22) years 14 (12-17) years 17 (15-18) years

Open table in a new tab

Conclusions

Deferred ADT until time of metastases results in long MFS and OS even with short PSADT suggesting that it remains possible that prolongation of MFS in nmCRPC may not reflect true overall net therapeutic benefits which requires prospective study to define specific patient selection and criteria for initial ADT implementation, control of post progression management and QoL/OS information.

annalsofoncology.org/articl...

Written by
George71 profile image
George71
To view profiles and participate in discussions please or .
Read more about...
7 Replies
Shooter1 profile image
Shooter1

Interesting to see those guys living so long... BUT, when you start with mets in lymph nodes and bones and rising PSA after RP, you need to jump in and attack it... At least that was the advice of my urologist, MO and RO. Still here at 5 year mark so they must not have been to far off in their advice... Life Is Good, especially more and more abundantly...

George71 profile image
George71 in reply toShooter1

You are doing the right thing -- and it looks like it is working great. The BCR protocol wasn't for you.

maley2711 profile image
maley2711 in reply toShooter1

that doesn't seem to contradict the study...you had metastasis, so start ADT!!

maley2711 profile image
maley2711

yet we do ADT for radiation + ADT for intermediate /high risk PCa men without metastasis?

George71 profile image
George71 in reply tomaley2711

Yes, -- it doesn't make since --- that was what kept me from doing radiation ..... In 2016 I tried for 3 months to get a Dr. to give me radiation WITHOUT ADT but none would -- so I did surgery -- my Dad and 2 uncles had radiation 25 + years prior without ADT and were cured. The R/O I wanted to use insisted I agree to 24 months of ADT.

j-o-h-n profile image
j-o-h-n

Hello George. I was blessed already with overall survival when my crazy ex-wife left me.........

Hallelujah, Hallelujah. In the almighty words of Martin Luther King "free at last, free at last thank God Almighty, I am free at last!"

Good Luck, Good Health and Good Humor.

j-o-h-n Friday 04/01/2022 6:00 PM DST

George71 profile image
George71 in reply toj-o-h-n

LOL !

Not what you're looking for?

You may also like...

When Is ADT Right for Biochemically Recurrent Prostate Cancer? Study suggest early initiation may not "meaningfully" improve survival

In a retrospective study, men with a prostate-specific antigen doubling time (PSADT) of less than...
George71 profile image

More data from the LATITUDE study.

New paper below [1]. "At 6 mo, 40% receiving AAP {abiraterone acetate and prednisone} + ADT and...
pjoshea13 profile image

ASCO 2019: Outcomes of Men with Recurrent M0 Prostate Cancer who Defer Androgen Deprivation Therapy until Metastasis

"This abstract retrospective reviews 2,636 men who had radical prostatectomy between 1981 and 2017...
George71 profile image

Modified Citrus Pectin - reply from Dr Eliaz

A member asked me to post the reply I was to get from Dr Isaac Eliaz on MCP, Modified Citrus Pectin...
Purple-Bike profile image

Overall Survival With [177]Lu-PSMA-617 vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

The Lancet Oncology TAKE-HOME MESSAGE TheraP was a phase II trial that compared the efficacy of...
Magnus1964 profile image